The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression
Related Experiment Video
Updated: Aug 16, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
A K Samraj1, C Stroh, U Fischer
1Institute of Molecular Medicine, University of Düsseldorf, Germany.
Abstract:
Tyrosine kinases of the Src family have been implicated in key biological processes. Here, we provide evidence that p56(Lck), a lymphoid-specific Src kinase, is involved in the activation of the mitochondrial apoptosis pathway. Lck-deficient T cells were completely resistant to anticancer drugs. In contrast, apoptosis sensitivity to death receptors was not altered, indicating a specific interference of Lck with the mitochondrial pathway. Re-expression of Lck restored sensitivity to drug-induced apoptosis and triggered mitochondrial cytochrome c release and caspase activation. Further analysis identified that the sensitization by Lck was independent of classical mediators of T-cell signaling, but essentially involved the Bcl-2 protein Bak. Expression of Bak was completely absent in Lck-deficient cells, while re-expression of Lck transcriptionally triggered Bak expression and conferred sensitivity to apoptosis, associated with a proapoptotic conformational change of Bak. Furthermore, in vitro the truncated fragment of Bid specifically activated Bak and cytochrome c release only from mitochondria of Lck-expressing cells. These results do not only demonstrate a sentinel role of Lck in drug resistance but also delineate a hitherto unknown pathway of Src kinases in regulation of Bcl-2 proteins.
Insights
The lymphoid-specific Src kinase p56(Lck) regulates mitochondrial apoptosis. Lck deficiency confers drug resistance by blocking Bak expression, while Lck re-expression restores sensitivity via Bak activation.
Area of Science:
- Cell Biology
- Molecular Biology
- Immunology
Background:
- Src family kinases (SFKs) are crucial in cellular signaling.
- p56(Lck) is a lymphoid-specific SFK involved in T-cell function.
- The role of Lck in apoptosis, particularly the mitochondrial pathway, is not fully understood.
Purpose of the Study:
- To investigate the role of p56(Lck) in drug-induced apoptosis.
- To elucidate the specific pathway through which Lck influences apoptosis.
- To identify downstream targets of Lck in the apoptotic process.
Main Methods:
- Utilized Lck-deficient T cells and Lck-reconstituted cells.
- Assessed sensitivity to anticancer drugs and death receptor-mediated apoptosis.
- Analyzed mitochondrial cytochrome c release, caspase activation, and Bcl-2 protein expression (Bak).
- Investigated the transcriptional regulation of Bak by Lck.
- Performed in vitro assays using truncated Bid to assess Bak activation.
Main Results:
- Lck-deficient T cells exhibited complete resistance to anticancer drugs but normal sensitivity to death receptors.
- Re-expression of Lck restored drug sensitivity, triggering cytochrome c release and caspase activation.
- Lck-mediated sensitization was independent of classical T-cell signaling but critically involved Bak.
- Lck deficiency resulted in absent Bak expression; Lck re-expression induced Bak transcription and activation.
- Lck-expressing cells showed enhanced Bak-mediated cytochrome c release upon Bid activation.
Conclusions:
- p56(Lck) plays a critical role in regulating the mitochondrial apoptosis pathway, specifically in response to anticancer drugs.
- Lck acts as a sentinel in drug resistance by transcriptionally inducing the expression and activation of the proapoptotic protein Bak.
- This study reveals a novel pathway for Src kinases in regulating Bcl-2 family proteins and offers potential therapeutic targets for overcoming drug resistance.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Cellular Injury V: Apoptosis and Autophagy
Apoptosis

